ectiecinib

Ectiecinib is an experimental pharmaceutical investigated as part of a combination therapy for metastatic non-squamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations. It has been evaluated in clinical trials together with pemetrexed and platinum-based chemotherapy, specifically for patients who did not progress after initial pemetrexed/platinum treatment[2][4][6][8][10]. Detailed information on ectiecinib’s mechanism of action, molecular target, developer, and modality is currently not publicly available in major regulatory or pharmaceutical databases. The available clinical data only describe its use in a combination regimen as part of a study population with EGFR-mutant NSCLC.